1
|
Li C, Cao S, Sun X, Lu C, Guo M. Prognostic modeling of overall survival and analysis of K-M survival curves in patients with primary colon cancer: A SEER-based study. Medicine (Baltimore) 2023; 102:e33902. [PMID: 37335675 DOI: 10.1097/md.0000000000033902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/21/2023] Open
Abstract
This study aimed to establish a validated prognostic survival column line chart by analyzing data from patients with colon cancer (CC) in the SEER database. The nomogram proposed in this study was based on the retrospective data of patients diagnosed with CC in the SEER database from 1975 to 2015. Randomly divided into training and validation sets, the nomogram was constructed using the Cox model, and the discriminatory power of the nomogram and its predictive accuracy were determined using the consistency index and associated calibration curves. In a multifactorial analysis of the main cohort, the independent factors for survival were age, sex, race, tumor stage, and tumor grade, all of which were included in the nomogram and were prognostic factors for patients with CC (P < .05). The calibration curve of the survival probability showed good agreement between the prediction of the nomogram and the actual observation. The validation calibration curve showed good correlation and agreement between predicted and observed values. Multifactorial analysis showed that the factors affecting the prognosis of patients with CC included age, sex, race, tumor-node-metastasis stage, and tumor pathological stage. The nomogram prediction model proposed in this study has high accuracy and can provide more accurate prognostic prediction and relevant reference values for assessing the postoperative survival of CC patients and guiding clinical decision-making.
Collapse
Affiliation(s)
- Chongyang Li
- Second Clinical Medical College, Binzhou Medical University, Yantai, China
- Department of General Surgery Center, Linyi People's Hospital, Shandong University, Linyi, China
| | | | - Xuedi Sun
- Department of General Surgery Center, Linyi People's Hospital, Shandong University, Linyi, China
- Jinzhou Medical University, Jinzhou, China
| | - Chunlei Lu
- Department of General Surgery Center, Linyi People's Hospital, Shandong University, Linyi, China
| | - Mingxiao Guo
- Department of General Surgery Center, Linyi People's Hospital, Shandong University, Linyi, China
| |
Collapse
|
2
|
Baranda JC, Diaz FJ, Rubinstein L, Shields AF, Dayyani F, Mehta A, Mehnert JM, Trent J, Mabaera R, Mooney M, Moscow JA, Doroshow J, Waters B, Ivy P, Gore SD, Thomas A. Expanding access to early phase trials: the CATCH-UP.2020 experience. JNCI Cancer Spectr 2023; 7:pkac087. [PMID: 36525371 PMCID: PMC9825762 DOI: 10.1093/jncics/pkac087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 09/01/2022] [Accepted: 12/07/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Disparities in cancer outcomes persist for underserved populations; one important aspect of this is limited access to promising early phase clinical trials. To address this, the National Cancer Institute-funded Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP.2020) was created. We report the tools developed and accrual metrics of the initial year of CATCH-UP.2020 with a focus on racial, ethnic, geographic, and socioeconomically underserved populations. METHODS CATCH-UP.2020 is a P30 supplement awarded to 8 National Cancer Institute-designated cancer centers with existing resources to rapidly open and accrue to Experimental Therapeutics Clinical Trials Network (ETCTN) trials with emphasis on engaging patients from underserved populations. Sites used patient-based, community-based, investigator-based, and program-based tools to meet specific program goals. RESULTS From September 2020 to August 2021, CATCH-UP.2020 sites opened 45 ETCTN trials. Weighted average trial activation time for the 7 sites reporting this was 107 days. In the initial year, sites enrolled 145 patients in CATCH-UP.2020 with 68 (46.9%) representing racial, ethnic, rural, and socioeconomically underserved populations using the broader definition of underserved encompassed in the grant charge. During the initial year of CATCH-UP.2020, a time impacted by the COVID-19 pandemic, 15.8% (66 of 417) and 21.4% (31 of 145) of patients enrolled to ETCTN trials at network and at CATCH-UP sites, respectively, were from racial and ethnic minority groups, a more limited definition of underserved for which comparable data are available. CONCLUSION Targeted funding accelerated activation and accrual of early phase trials and expanded access to this therapeutic option for underserved populations.
Collapse
Affiliation(s)
- Joaquina C Baranda
- Department of Medical Oncology, University of Kansas Cancer Center, Kansas City, KS, USA
| | - Francisco J Diaz
- Department of Biostatistics & Data Science, The University of Kansas Medical Center, Kansas City, KS, USA
| | - Larry Rubinstein
- National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
| | - Anthony F Shields
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
| | - Farshid Dayyani
- Division of Hematology/Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center-University of California Irvine, Irvine, CA, USA
| | - Amitkumar Mehta
- Division of Hematology and Oncology, Department of Internal Medicine, O’Neal Comprehensive Cancer Center-University of Alabama at Birmingham, Birmingham, AL, USA
| | - Janice M Mehnert
- Department of Internal Medicine, Perlmutter Cancer Center of NYU Langone, NYU Grossman School of Medicine, New York, NY, USA
| | - Jonathan Trent
- Department of Internal Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Rodwell Mabaera
- Section of Medical Oncology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA
| | - Margaret Mooney
- National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
| | - Jeffrey A Moscow
- National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
| | - James Doroshow
- National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
| | - Brittany Waters
- National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
| | - Percy Ivy
- National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
| | - Steven D Gore
- National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
| | - Alexandra Thomas
- Department of Internal Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA
| |
Collapse
|